A Randomized, Double-Blind, Placebo-Controlled, 52-Week Phase II Study to Evaluate the Efficacy of Intravenous RO7046015 (PRX002) in Participants With Early Parkinson's Disease With a 52-Week Blinded Extension
Phase of Trial: Phase II
Latest Information Update: 22 Dec 2017
At a glance
- Drugs PRX 002 (Primary)
- Indications Parkinson's disease
- Focus Therapeutic Use
- Acronyms PASADENA
- Sponsors Roche
- 16 Nov 2017 According to a Prothena media release, highlights from the study will be discussed during R&D Day.
- 25 Sep 2017 Planned End Date changed from 19 Jun 2021 to 29 Jun 2021.
- 11 Sep 2017 Planned End Date changed from 19 Oct 2020 to 19 Jun 2021.